Henning Blume-How relevant are drug-food interactions.pdf(269 kB)
Risks arising from pharmacokinetics and biopharmaceutics: How relevant are drug-food interactions?
Breithaupt K., Sourgens, H.
Breithaupt K. und Sourgens H. – Healthy subjects Annual Meeting 2014 website.pdf(2.6 MB)
When is a subject healthy – results of the AGAH workshops
Susen Burock-Risk benefit assessment for new forms of clinical research.pdf(0.9 MB)
Risks/benefits assessment for new forms of clinical research in the era of molecular biology
Diefenbach K. 13032014.pdf
Ethnik differences which may affect safety/tolerability
Stipo Jurcevic-False positive and false negative biomarkers.pdf(2.9 MB)
False posive and false negative biomarkers
Ingrid Klingmann-Decreasing risk by Investigator training.pdf(872 kB)
Decreaing Risk by Investigator Training: European Training Concepts
Karl-Heinz Konopka-Predictivity of Pain Models.pdf(2.1 MB)
Predictivity of Pain Models
AGAH Annual meeting 2014 final AK.pdf(1.9 MB)
Attrition in clinical development: the earlier, the better? – an introduction into the conference
Dagmar Kubitza-Biomarkers for new anticoagulants – vice and virtue.pdf(1.1 MB)
Biomarkers for new anticoagulants – vice and virtue
Mikus, G. / Oberwittler H.
Gerd Mikus Heike Oberwittler-How to decrease risks in early development of oncological drugs.pdf(273 kB)
How to decrease/manage risk in early development of oncology drugs
Wolfgang Muster-Early Non-clinical Characterisation of Drugs in Development.pdf(4.0 MB)
Early non-clinical characterisation of drugs in development
Stephanie Plassmann-Predictivity of toxicological findings for first-in-man safety.pdf(93 kB)
Predictivity of toxicological findings for first-in-man safety
Jens Rengelshausen-Drug-drug interactions that really matter-focus on transporters.pdf(494 kB)
Drug-drug interactions that really matter – focus on transporters
Jennifer Sims-Early safety assessment of biologicals.pdf(1.6 MB)
Early safety assessment of biologicals
Jorg Taubel-QT assessment in a first-in-man trial – is the earlier really the better.pdf(1.2 MB)
QT assessment in a first in man trial – is the earlier really the better?
van Iersel, T.
Thijs van Iersel-Phase 1 mitigation in high risk compounds.pdf(4.0 MB)
Phase I risk mitigation in high risk compounds.